Welcome to our dedicated page for Zepp Health SEC filings (Ticker: ZEPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zepp Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zepp Health's regulatory disclosures and financial reporting.
FIL Limited, together with affiliated entities including Pandanus Partners, L.P. and Pandanus Associates, Inc., reports beneficial ownership of 11,490,848 shares of Zepp Health Corp Class A common stock on an amended Schedule 13G.
This position represents 8.5% of the outstanding Class A common stock as of June 30, 2026. FIL Limited reports sole voting power over 11,490,848 shares, while Pandanus entities report no voting power but sole dispositive power over the same number of shares. One or more other persons have rights to dividends or sale proceeds, but no such person holds more than five percent of the class.
Zepp Health Corp Chief Technology Officer Meihui Fan exercised options to acquire 520,000 Class A ordinary shares on June 26, 2026. These shares are held indirectly through Fandler Holding Limited, an entity ultimately owned by a trust established for the benefit of Mr. Fan and his family members.
Following the transactions, Fandler Holding Limited held 952,000 Class A ordinary shares. The filing shows multiple option grants, each with an exercise or conversion price of $0.0000 per share, being converted into Class A ordinary shares, with no reported share sales in this filing.
Zepp Health Corp’s Chief Financial Officer, Deng Cheng, reported compensation-related equity activity involving American depositary shares (ADSs) and restricted share units (RSUs). On June 26, 2026, 366,000 RSUs, each representing one Class A ordinary share, vested and were settled into ADSs, with each ADS representing 16 Class A ordinary shares. This conversion delivered 22,875 ADSs at no cost to the CFO.
On the same date, 9,836 ADSs were sold in the open market at a weighted average price of $4.61 per ADS in a sell-to-cover transaction to pay tax withholding obligations tied to the RSU vesting. Following these transactions, the CFO directly holds 114,539 ADSs, indicating that most of the vested equity was retained as ongoing ownership.
Zepp Health Corp Schedule 13G filing reports that Morgan Stanley (through reporting units) beneficially holds 8,472,224 Class A Ordinary Shares / ADRs, representing 7.5% of the class. The filing lists shared voting power of 8,472,128 and shared dispositive power of 8,472,224, and is signed by an authorized Morgan Stanley signatory.
Zepp Health Corporation submitted a Rule 144 notice reporting securities to be sold in connection with the vesting of Restricted Share Units under its Share Incentive Plan. The filing references ADRs (each representing 16 Class A ordinary shares) and a vesting date of 06/26/2026.
The filing lists numeric fields including 9,836 and other reported figures. The entry identifies the ADR class and the vesting event; timing and the connection to the Share Incentive Plan are stated verbatim.
Zepp Health reported a strong start to 2026, with first‑quarter revenue rising 33.8% year over year to US$51.5 million, driven by new Amazfit products such as Active Max, Active 3 Premium, and T‑Rex Ultra 2. Amazfit‑branded revenue also grew 33.8% year over year, reflecting continued progress in its shift toward premium, Hybrid Training‑focused wearables.
Gross margin improved year over year to 37.7%, producing gross profit of US$19.4 million, but Zepp still posted a GAAP net loss of US$19.6 million and an adjusted net loss of US$17.9 million, both slightly narrower than a year ago. Cash and restricted cash totaled US$103.2 million and inventory fell to US$62.8 million, while cumulative debt retired since 2023 reached US$46.4 million. For the second quarter of 2026, management guides net revenue to US$63.0–68.0 million, implying about 6–14% growth versus the same quarter of 2025.
Zepp Health Corp reports an amended Schedule 13G/A showing 11,477,632 shares of Class A common stock beneficially owned, equal to 10.0% of the class as of 03/31/2026. The filing identifies FIL Limited and affiliated entities as the reporting holders.
The disclosure states that Fidelity Funds - China Focus holds 5,998,048 shares or 5.2% of Class A common stock as of 03/31/2026. Signatures show transactions are reported via power of attorney and include Exhibit 99 references.
Zepp Health Corporation files its annual report detailing a global smart wearables and health-technology business built around Amazfit, Zepp Clarity and Zepp Aura brands. For 2025, it generated $258.9M in revenue and reported a net loss of $40.1M.
The company operates through a Cayman holding structure with significant activities in China conducted via consolidated VIEs, whose revenue contribution fell from 40.1% in 2023 to 8.0% in 2025. Zepp highlights legal and operational risks from PRC regulation, VIE enforceability, data security oversight, and potential impacts of the HFCAA on U.S. trading.
Zepp changed its reporting currency from Renminbi to U.S. dollars in 2024 and effected an ADS ratio change so that one ADS now represents 16 Class A shares. As of December 31, 2025, it had 135,608,316 Class A and 99,277,687 Class B ordinary shares outstanding.
Zepp Health Corp director Xie Bing (Brian) has filed an initial statement of beneficial ownership on Form 3. The filing establishes his status as a director and does not report any insider buy, sell, or other share transactions.
Zepp Health Corp director Lai Jimmy Y. filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting insider under securities rules and does not report any stock purchases, sales, or other transactions in Zepp Health shares.